Free Trial
→ Buffett’s favorite chart just hit 209% – here’s what that means for gold (From Golden Portfolio) (Ad) Buy VERA Stock  Free VERA Stock Alerts

Vera Therapeutics (VERA) Financials

Vera Therapeutics logo
$25.31 +1.56 (+6.57%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$25.25 -0.06 (-0.24%)
As of 05/2/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Vera Therapeutics

Annual Income Statements for Vera Therapeutics

This table shows Vera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -53 -33 -89 -96 -152
Consolidated Net Income / (Loss)		 -53 -33 -89 -96 -152
Net Income / (Loss) Continuing Operations		 -53 -33 -89 -96 -152
Total Pre-Tax Income 		-53 -33 -89 -96 -152
Total Operating Income		 -52 -34 -91 -102 -167
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 52 34 91 102 167
Selling, General & Admin Expense		 4.04 12 22 24 41
Research & Development Expense		 45 22 69 78 126
Total Other Income / (Expense), net		 -1.17 1.79 1.85 6.02 15
Interest Expense		 0.17 0.02 0.99 3.79 7.63
Interest & Investment Income		 0.01 0.02 1.75 7.98 21
Other Income / (Expense), net		 -1.01 1.80 1.09 1.83 1.94
Income Tax Expense		 -0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($166.93) ($2.43) ($3.35) ($2.25) ($2.75)
Weighted Average Basic Shares Outstanding		 319.96K 13.44M 26.57M 42.71M 55.33M
Diluted Earnings per Share		 ($166.93) ($2.43) ($3.35) ($2.25) ($2.75)
Weighted Average Diluted Shares Outstanding		 319.96K 13.44M 26.57M 42.71M 55.33M
Weighted Average Basic & Diluted Shares Outstanding		 319.96K 13.44M 44.26M 54.45M 0.00

Quarterly Income Statements for Vera Therapeutics

This table shows Vera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -25 -32 -30 -20 -20 -26 -28 -34 -47 -43
Consolidated Net Income / (Loss)		 -25 -32 -30 -20 -20 -26 -28 -34 -47 -43
Net Income / (Loss) Continuing Operations		 -25 -32 -30 -20 -20 -26 -28 -34 -47 -43
Total Pre-Tax Income 		-25 -32 -30 -20 -20 -26 -28 -34 -47 -43
Total Operating Income		 -25 -34 -31 -22 -22 -27 -31 -37 -50 -49
Total Operating Expenses		 25 34 31 22 22 27 31 37 50 49
Selling, General & Admin Expense		 5.59 6.91 6.15 5.74 5.66 6.24 7.91 8.03 9.49 16
Research & Development Expense		 20 27 25 16 16 21 23 29 40 33
Total Other Income / (Expense), net		 0.57 1.14 1.19 1.81 1.65 1.37 2.73 3.64 3.17 5.49
Interest Expense		 0.15 0.60 0.87 0.91 0.94 1.06 1.91 1.91 1.94 1.87
Interest & Investment Income		 0.57 0.89 1.62 2.24 2.16 1.96 4.19 5.10 4.76 6.66
Other Income / (Expense), net		 0.15 0.85 0.44 0.48 0.44 0.47 0.45 0.44 0.34 0.70
Basic Earnings per Share		 ($0.91) ($1.18) ($0.80) ($0.46) ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72)
Weighted Average Basic Shares Outstanding		 27.22M 26.57M 37.67M 44.27M 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M
Diluted Earnings per Share		 ($0.91) ($1.18) ($0.80) ($0.46) ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72)
Weighted Average Diluted Shares Outstanding		 27.22M 26.57M 37.67M 44.27M 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M
Weighted Average Basic & Diluted Shares Outstanding		 27.66M 44.26M 44.26M 44.32M 44.43M 54.45M 54.70M 54.83M 63.32M 0.00

Annual Cash Flow Statements for Vera Therapeutics

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 19 26 -36 1.93 47
Net Cash From Operating Activities		 -35 -24 -68 -92 -135
Net Cash From Continuing Operating Activities		 -66 -24 -68 -92 -135
Net Income / (Loss) Continuing Operations		 -53 -33 -89 -96 -152
Consolidated Net Income / (Loss)		 -53 -33 -89 -96 -152
Depreciation Expense		 0.25 0.18 -0.85 0.02 0.11
Amortization Expense		 - - - -4.11 -8.16
Non-Cash Adjustments To Reconcile Net Income		 18 1.21 13 14 23
Changes in Operating Assets and Liabilities, net		 0.12 7.51 9.35 -5.82 2.66
Net Cash From Investing Activities		 -0.04 -4.20 -71 -39 -425
Net Cash From Continuing Investing Activities		 -0.04 -4.20 -71 -39 -425
Purchase of Property, Plant & Equipment		 -0.10 -5.00 -0.06 -0.06 -0.97
Purchase of Investments		 - 0.00 -148 -225 -703
Sale and/or Maturity of Investments		 - 0.00 78 186 279
Net Cash From Financing Activities		 85 54 102 134 607
Net Cash From Continuing Financing Activities		 86 54 102 134 607
Repayment of Debt		 -0.02 4.92 - 25 0.00
Repurchase of Common Equity		 0.00 -2.77 - 0.00 -0.01
Issuance of Common Equity		 0.00 52 88 116 646
Other Financing Activities, net		 0.10 0.00 14 -7.26 -39
Cash Interest Paid		 0.03 0.02 0.90 3.35 6.65

Quarterly Cash Flow Statements for Vera Therapeutics

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -20 13 94 -104 -6.45 18 23 -44 2.17 65
Net Cash From Operating Activities		 -18 -21 -26 -18 -23 -25 -34 -25 -37 -39
Net Cash From Continuing Operating Activities		 -18 -21 -26 -18 -23 -25 -34 -25 -37 -39
Net Income / (Loss) Continuing Operations		 -25 -32 -30 -20 -20 -26 -28 -34 -47 -43
Consolidated Net Income / (Loss)		 -25 -32 -30 -20 -20 -26 -28 -34 -47 -43
Depreciation Expense		 -0.15 -0.60 -0.51 0.52 0.01 0.00 -1.47 1.50 0.02 0.06
Amortization Expense		 - - - - -3.09 -1.17 - - -6.70 -1.85
Non-Cash Adjustments To Reconcile Net Income		 6.23 2.65 2.57 2.29 5.11 3.75 4.00 1.54 11 6.77
Changes in Operating Assets and Liabilities, net		 0.18 9.23 1.72 -0.57 -4.90 -2.08 -7.98 5.51 5.86 -0.73
Net Cash From Investing Activities		 -2.44 13 12 -86 16 19 -219 -23 38 -221
Net Cash From Continuing Investing Activities		 -2.44 13 12 -86 16 19 -219 -23 38 -221
Purchase of Property, Plant & Equipment		 -0.04 - - - - -0.06 - - -0.24 -0.65
Purchase of Investments		 -40 -11 -34 -109 -29 -53 -255 -81 -73 -294
Sale and/or Maturity of Investments		 38 24 46 22 45 72 36 59 112 73
Net Cash From Financing Activities		 0.91 21 108 0.43 0.30 25 277 3.44 0.74 326
Net Cash From Continuing Financing Activities		 0.91 21 108 0.43 0.30 25 277 3.44 0.74 326
Issuance of Common Equity		 0.98 0.83 115 0.43 0.30 0.09 294 3.44 0.75 347
Other Financing Activities, net		 -0.07 20 -7.26 - - - -18 - - -21
Cash Interest Paid		 0.12 0.56 3.25 -1.62 0.86 0.85 1.52 1.73 1.74 1.66

Annual Balance Sheets for Vera Therapeutics

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 55 84 131 176 656
Total Current Assets		 54 83 126 172 651
Cash & Equivalents		 54 80 43 46 93
Short-Term Investments		 - 0.00 71 115 548
Prepaid Expenses		 0.56 2.86 11 11 10
Plant, Property, & Equipment, net		 0.00 0.00 0.05 0.09 0.96
Total Noncurrent Assets		 0.29 1.21 5.69 3.43 3.50
Other Noncurrent Operating Assets		 0.29 0.34 5.63 3.43 3.50
Total Liabilities & Shareholders' Equity		 55 84 131 176 656
Total Liabilities		 4.33 14 55 74 79
Total Current Liabilities		 2.41 7.69 26 22 25
Accounts Payable		 0.91 1.39 12 11 7.67
Accrued Expenses		 0.54 5.93 11 8.75 16
Other Current Liabilities		 0.96 0.38 2.65 2.44 1.48
Total Noncurrent Liabilities		 1.92 6.47 29 52 53
Long-Term Debt		 - 4.92 25 50 51
Other Noncurrent Operating Liabilities		 0.29 0.29 4.12 1.68 2.47
Total Equity & Noncontrolling Interests		 -89 70 77 102 577
Total Preferred & Common Equity		 -89 70 77 102 577
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -89 70 77 102 577
Common Stock		 2.10 194 290 410 1,038
Retained Earnings		 -91 -124 -213 -309 -461
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.22 0.25 0.39

Quarterly Balance Sheets for Vera Therapeutics

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 131 210 195 176 419 397 369
Total Current Assets		 125 204 191 172 416 395 364
Cash & Equivalents		 30 137 34 27 69 25 27
Short-Term Investments		 84 60 147 132 335 359 326
Prepaid Expenses		 11 7.30 9.59 12 13 10 11
Plant, Property, & Equipment, net		 0.06 0.05 0.04 0.03 0.08 0.16 0.37
Total Noncurrent Assets		 6.33 5.11 4.52 3.96 2.91 2.39 4.06
Other Noncurrent Operating Assets		 6.21 5.05 4.50 3.95 2.91 2.39 4.06
Total Liabilities & Shareholders' Equity		 131 210 195 176 419 397 369
Total Liabilities		 26 52 55 52 66 69 80
Total Current Liabilities		 16 24 27 25 15 18 26
Accounts Payable		 7.01 5.33 13 12 5.21 4.66 4.60
Accrued Expenses		 6.22 16 11 9.80 7.06 12 20
Other Current Liabilities		 2.69 2.60 2.56 2.52 2.28 2.12 1.87
Total Noncurrent Liabilities		 9.73 28 28 27 51 51 53
Long-Term Debt		 4.97 25 25 25 50 50 50
Other Noncurrent Operating Liabilities		 4.77 3.48 2.86 2.25 1.21 0.74 2.57
Total Equity & Noncontrolling Interests		 106 158 141 124 354 328 289
Total Preferred & Common Equity		 106 158 141 124 354 328 289
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 106 158 141 124 354 328 289
Common Stock		 287 401 404 407 691 700 706
Retained Earnings		 -181 -243 -263 -283 -337 -371 -418
Accumulated Other Comprehensive Income / (Loss)		 -0.28 -0.00 -0.14 -0.08 -0.17 -0.45 1.04

Annual Metrics and Ratios for Vera Therapeutics

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 38.82% -179.58% -15.01% -66.20%
EBIT Growth		 0.00% 38.78% -175.47% -11.55% -64.93%
NOPAT Growth		 0.00% 34.15% -164.24% -12.22% -63.87%
Net Income Growth		 0.00% 38.95% -173.10% -7.79% -58.50%
EPS Growth		 0.00% 98.54% -37.86% 32.84% -22.22%
Operating Cash Flow Growth		 0.00% 31.89% -185.12% -36.37% -46.10%
Free Cash Flow Firm Growth		 0.00% 0.00% -163.17% -32.79% -50.39%
Invested Capital Growth		 0.00% -73.36% -115.62% 29.55% -42.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 45.16% -22.30% 2.50% -17.38%
EBIT Q/Q Growth		 0.00% 44.39% -21.51% 5.81% -15.08%
NOPAT Q/Q Growth		 0.00% 43.02% -23.00% 6.04% -15.06%
Net Income Q/Q Growth		 0.00% 44.39% -21.22% 6.60% -13.22%
EPS Q/Q Growth		 0.00% 98.35% -140.26% 22.15% -7.00%
Operating Cash Flow Q/Q Growth		 0.00% 46.91% -27.85% -4.51% -11.64%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -14.00% -9.61% -14.17%
Invested Capital Q/Q Growth		 0.00% -229.65% -236.78% 18.29% 5.59%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.30% 100.02% 99.16% 95.81% 92.08%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -106.34% -54.43% -121.58% -107.50% -44.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 189.16% 8.97% -121.55% -107.45% -44.82%
Return on Equity Simple (ROE_SIMPLE)		 59.78% -46.86% -115.80% -94.40% -26.36%
Net Operating Profit after Tax (NOPAT)		 -37 -24 -64 -71 -117
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -31.37% -13.19% -30.72% -24.49% -10.02%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -47.12% -18.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -53 -33 -90 -100 -165
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -32 -91 -104 -173
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 8.17 6.96 6.72 4.64
Price to Tangible Book Value (P/TBV)		 0.00 8.17 6.96 6.72 4.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.07 0.32 0.49 0.09
Long-Term Debt to Equity		 0.00 0.07 0.32 0.49 0.09
Financial Leverage		 -1.07 -1.08 -1.13 -1.12 -1.03
Leverage Ratio		 1.09 1.15 1.47 1.72 1.22
Compound Leverage Factor		 1.09 1.15 1.46 1.65 1.13
Debt to Total Capital		 0.00% 6.61% 24.39% 32.91% 8.07%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 6.61% 24.39% 32.91% 8.07%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 277.88% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -177.88% 93.39% 75.58% 67.06% 91.93%
Debt to EBITDA		 0.00 -0.15 -0.27 -0.48 -0.29
Net Debt to EBITDA		 0.00 2.33 0.99 1.06 3.41
Long-Term Debt to EBITDA		 0.00 -0.15 -0.27 -0.48 -0.29
Debt to NOPAT		 0.00 -0.20 -0.39 -0.70 -0.43
Net Debt to NOPAT		 0.00 3.14 1.41 1.55 5.04
Long-Term Debt to NOPAT		 0.00 -0.20 -0.39 -0.70 -0.43
Altman Z-Score		 2.21 21.81 2.28 2.23 19.79
Noncontrolling Interest Sharing Ratio		 277.88% 116.49% 0.02% 0.04% 0.01%
Liquidity Ratios		 - - - - -
Current Ratio		 22.55 10.73 4.91 7.71 25.67
Quick Ratio		 22.30 10.36 4.48 7.21 25.26
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -22 -57 -75 -113
Operating Cash Flow to CapEx		 -82,878.57% -474.16% -109,025.81% -146,319.05% -13,855.86%
Free Cash Flow to Firm to Interest Expense		 0.00 -1,076.57 -57.12 -19.88 -14.84
Operating Cash Flow to Interest Expense		 -209.69 -1,185.40 -68.14 -24.35 -17.66
Operating Cash Flow Less CapEx to Interest Expense		 -209.95 -1,435.40 -68.20 -24.36 -17.79
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -3.48 -6.03 -13 -9.15 -13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.55 -6.97 3.84 -3.86
Enterprise Value (EV)		 134 493 445 573 2,088
Market Capitalization		 48 569 535 683 2,678
Book Value per Share		 ($279.24) $3.27 $2.78 $2.29 $9.11
Tangible Book Value per Share		 ($279.24) $3.27 $2.78 $2.29 $9.11
Total Capital		 50 75 102 152 628
Total Debt		 0.00 4.92 25 50 51
Total Long-Term Debt		 0.00 4.92 25 50 51
Net Debt		 -54 -76 -90 -111 -590
Capital Expenditures (CapEx)		 0.04 5.00 0.06 0.06 0.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.85 -4.83 -15 -11 -15
Debt-free Net Working Capital (DFNWC)		 52 75 100 150 626
Net Working Capital (NWC)		 52 75 100 150 626
Net Nonoperating Expense (NNE)		 17 8.53 25 25 35
Net Nonoperating Obligations (NNO)		 -54 -76 -90 -111 -590
Total Depreciation and Amortization (D&A)		 0.25 0.18 -0.85 -4.09 -8.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.43) ($3.35) ($2.25) ($2.75)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 27.05M 26.57M 42.71M 55.33M
Adjusted Diluted Earnings per Share		 $0.00 ($2.43) ($3.35) ($2.25) ($2.75)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 27.05M 26.57M 42.71M 55.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.43) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.44M 44.26M 54.45M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -34 -24 -64 -71 -117
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -320.81 -1,630.15 -90.54 -26.46 -21.67
NOPAT to Interest Expense		 -220.29 -1,204.07 -64.15 -18.86 -15.34
EBIT Less CapEx to Interest Expense		 -321.06 -1,880.15 -90.60 -26.48 -21.79
NOPAT Less CapEx to Interest Expense		 -220.55 -1,454.07 -64.21 -18.88 -15.47
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -8.48% 0.00% 0.00% -0.01%

Quarterly Metrics and Ratios for Vera Therapeutics

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -234.14% -98.39% -84.43% -38.93% 3.36% 16.82% -2.58% -68.84% -130.03% -80.38%
EBIT Growth		 -229.56% -94.47% -81.36% -43.36% 15.06% 18.86% 0.50% -71.73% -131.99% -81.55%
NOPAT Growth		 -248.10% -102.48% -83.64% -45.91% 13.82% 19.51% 0.47% -69.97% -128.91% -80.98%
Net Income Growth		 -224.25% -92.55% -76.00% -35.74% 18.54% 20.91% 5.61% -67.19% -131.95% -69.27%
EPS Growth		 -152.78% -111.25% -12.68% 16.36% 50.55% 54.24% 30.00% -34.78% -88.89% -33.33%
Operating Cash Flow Growth		 -235.89% -228.70% -192.75% 6.63% -24.72% -18.82% -28.67% -39.44% -60.56% -55.83%
Free Cash Flow Firm Growth		 -381.49% -82.57% -536.00% 2.30% 49.59% -37.60% -87.10% -531.91% -309.46% -33.50%
Invested Capital Growth		 -111.05% -115.62% -20.23% -168.55% -190.38% 29.55% 99.62% 59.81% -23.01% -42.12%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -67.29% -31.99% 6.02% 33.05% -16.37% -13.62% -15.90% -10.19% -58.54% 10.91%
EBIT Q/Q Growth		 -67.46% -30.42% 5.85% 30.28% 0.78% -24.57% -15.46% -20.34% -34.03% 2.51%
NOPAT Q/Q Growth		 -67.66% -33.03% 6.92% 29.71% 0.97% -24.23% -15.11% -20.03% -33.36% 1.78%
Net Income Q/Q Growth		 -66.16% -31.44% 7.31% 32.95% 0.29% -27.61% -10.63% -18.76% -38.34% 6.88%
EPS Q/Q Growth		 -65.45% -29.67% 32.20% 42.50% 2.17% -20.00% -3.70% -10.71% -37.10% 15.29%
Operating Cash Flow Q/Q Growth		 3.22% -14.89% -24.24% 32.41% -29.27% -9.45% -34.55% 26.75% -48.84% -6.23%
Free Cash Flow Firm Q/Q Growth		 -172.40% -5.75% -17.42% 71.11% -40.54% -188.66% -59.66% 2.44% 8.93% 5.88%
Invested Capital Q/Q Growth		 33.44% -236.78% -12.48% -6.50% 28.02% 18.29% 99.39% -11,069.64% -120.32% 5.59%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.33% 99.10% 97.57% 93.83% 94.30% 96.60% 92.56% 91.35% 94.29% 90.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -76.85% -121.58% -69.86% -81.94% -89.59% -107.50% -36.89% -46.05% -65.11% -44.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -76.85% -121.55% -69.85% -81.94% -89.59% -107.45% -36.89% -46.05% -65.10% -44.82%
Return on Equity Simple (ROE_SIMPLE)		 -69.49% 0.00% -64.70% -76.39% -83.08% 0.00% -26.67% -32.89% -46.49% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -24 -22 -15 -15 -19 -22 -26 -35 -34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.12% -10.79% -5.14% -3.38% -3.99% -6.71% -2.51% -3.09% -5.38% -2.62%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -12.48% - - - -5.45%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -25 -33 -31 -21 -21 -27 -31 -37 -49 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -33 -31 -21 -24 -28 -32 -35 -56 -50
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 5.47 6.96 2.18 5.06 4.91 6.72 6.64 6.04 8.39 4.64
Price to Tangible Book Value (P/TBV)		 5.47 6.96 2.18 5.06 4.91 6.72 6.64 6.04 8.39 4.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.05 0.32 0.16 0.18 0.20 0.49 0.14 0.15 0.17 0.09
Long-Term Debt to Equity		 0.05 0.32 0.16 0.18 0.20 0.49 0.14 0.15 0.17 0.09
Financial Leverage		 -1.03 -1.13 -1.09 -1.08 -1.07 -1.12 -1.03 -1.05 -1.06 -1.03
Leverage Ratio		 1.16 1.47 1.28 1.31 1.34 1.72 1.23 1.26 1.32 1.22
Compound Leverage Factor		 1.14 1.46 1.25 1.23 1.26 1.66 1.14 1.16 1.24 1.10
Debt to Total Capital		 4.49% 24.39% 13.63% 15.08% 16.84% 32.91% 12.40% 13.29% 14.86% 8.07%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.49% 24.39% 13.63% 15.08% 16.84% 32.91% 12.40% 13.29% 14.86% 8.07%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 95.51% 75.58% 86.37% 84.92% 83.16% 67.06% 87.60% 86.71% 85.12% 91.93%
Debt to EBITDA		 -0.07 -0.27 -0.24 -0.23 -0.23 -0.48 -0.48 -0.42 -0.34 -0.29
Net Debt to EBITDA		 1.48 0.99 1.64 1.41 1.26 1.06 3.37 2.80 2.05 3.41
Long-Term Debt to EBITDA		 -0.07 -0.27 -0.24 -0.23 -0.23 -0.48 -0.48 -0.42 -0.34 -0.29
Debt to NOPAT		 -0.10 -0.39 -0.34 -0.32 -0.33 -0.70 -0.70 -0.61 -0.50 -0.43
Net Debt to NOPAT		 2.12 1.41 2.34 1.99 1.78 1.55 4.96 4.07 2.98 5.04
Long-Term Debt to NOPAT		 -0.10 -0.39 -0.34 -0.32 -0.33 -0.70 -0.70 -0.61 -0.50 -0.43
Altman Z-Score		 11.97 3.71 2.90 6.55 5.37 3.61 21.19 16.63 17.36 20.38
Noncontrolling Interest Sharing Ratio		 0.00% 0.02% 0.01% 0.00% 0.00% 0.04% 0.00% 0.00% 0.01% 0.01%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 7.85 4.91 8.69 7.10 6.97 7.71 28.63 21.43 13.76 25.67
Quick Ratio		 7.19 4.48 8.38 6.75 6.50 7.21 27.76 20.87 13.35 25.26
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -17 -19 -5.61 -7.88 -23 -36 -35 -32 -30
Operating Cash Flow to CapEx		 -48,473.68% 0.00% 0.00% 0.00% 0.00% -39,911.11% 0.00% 0.00% -15,497.90% -6,074.73%
Free Cash Flow to Firm to Interest Expense		 -106.40 -27.61 -22.22 -6.14 -8.36 -21.57 -19.06 -18.54 -16.67 -16.23
Operating Cash Flow to Interest Expense		 -125.31 -35.33 -30.08 -19.44 -24.36 -23.83 -17.75 -12.96 -19.05 -20.93
Operating Cash Flow Less CapEx to Interest Expense		 -125.56 -35.33 -30.08 -19.44 -24.36 -23.89 -17.75 -12.96 -19.18 -21.28
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.86 -13 -15 -16 -11 -9.15 -0.06 -6.26 -14 -13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.03 -6.97 -2.46 -9.77 -7.35 3.84 15 9.31 -2.58 -3.86
Enterprise Value (EV)		 469 445 171 554 473 573 1,994 1,645 2,121 2,088
Market Capitalization		 578 535 343 710 608 683 2,348 1,979 2,423 2,678
Book Value per Share		 $3.90 $2.78 $3.56 $3.17 $2.79 $2.29 $6.49 $5.99 $5.27 $9.11
Tangible Book Value per Share		 $3.90 $2.78 $3.56 $3.17 $2.79 $2.29 $6.49 $5.99 $5.27 $9.11
Total Capital		 111 102 183 165 149 152 404 378 340 628
Total Debt		 4.97 25 25 25 25 50 50 50 50 51
Total Long-Term Debt		 4.97 25 25 25 25 50 50 50 50 51
Net Debt		 -110 -90 -172 -156 -135 -111 -354 -334 -303 -590
Capital Expenditures (CapEx)		 0.04 0.00 0.00 0.00 0.00 0.06 0.00 0.00 0.24 0.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.36 -15 -16 -17 -13 -11 -1.84 -8.06 -16 -15
Debt-free Net Working Capital (DFNWC)		 109 100 181 164 147 150 402 376 338 626
Net Working Capital (NWC)		 109 100 181 164 147 150 402 376 338 626
Net Nonoperating Expense (NNE)		 7.01 8.93 8.19 4.78 4.87 6.74 6.60 7.57 12 9.19
Net Nonoperating Obligations (NNO)		 -110 -90 -172 -156 -135 -111 -354 -334 -303 -590
Total Depreciation and Amortization (D&A)		 -0.15 -0.60 -0.51 0.52 -3.08 -1.17 -1.47 1.50 -6.68 -1.79
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.91) ($1.18) ($0.80) ($0.46) ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72)
Adjusted Weighted Average Basic Shares Outstanding		 27.22M 26.57M 37.67M 44.27M 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M
Adjusted Diluted Earnings per Share		 ($0.91) ($1.18) ($0.80) ($0.46) ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72)
Adjusted Weighted Average Diluted Shares Outstanding		 27.22M 26.57M 37.67M 44.27M 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.66M 44.26M 44.26M 44.32M 44.43M 54.45M 54.70M 54.83M 63.32M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -24 -22 -15 -15 -19 -22 -26 -35 -34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -170.74 -54.65 -35.26 -23.51 -22.61 -25.17 -16.09 -19.30 -25.55 -25.76
NOPAT to Interest Expense		 -120.21 -39.24 -25.04 -16.83 -16.15 -17.93 -11.43 -13.67 -18.01 -18.29
EBIT Less CapEx to Interest Expense		 -171.00 -54.65 -35.26 -23.51 -22.61 -25.23 -16.09 -19.30 -25.67 -26.10
NOPAT Less CapEx to Interest Expense		 -120.47 -39.24 -25.04 -16.83 -16.15 -17.99 -11.43 -13.67 -18.13 -18.64
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.01%

Frequently Asked Questions About Vera Therapeutics' Financials

When does Vera Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Vera Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Vera Therapeutics' net income changed over the last 4 years?

Vera Therapeutics' net income appears to be on an upward trend, with a most recent value of -$152.15 million in 2024, rising from -$53.41 million in 2020. The previous period was -$95.99 million in 2023. Find out what analysts predict for Vera Therapeutics in the coming months.

What is Vera Therapeutics's operating income?
Vera Therapeutics's total operating income in 2024 was -$167.17 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $167.17 million
How has Vera Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Vera Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Vera Therapeutics have?

Vera Therapeutics' total liabilities were at $78.53 million at the end of 2024, a 6.3% increase from 2023, and a 1,715.2% increase since 2020.

How much cash does Vera Therapeutics have?

In the past 4 years, Vera Therapeutics' cash and equivalents has ranged from $43.46 million in 2022 to $92.65 million in 2024, and is currently $92.65 million as of their latest financial filing in 2024.

How has Vera Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Vera Therapeutics' book value per share changed from -279.24 in 2020 to 9.11 in 2024, a change of -103.3%.


Related Companies

This page (NASDAQ:VERA) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored
U.S. Stock Market Now on Verge of Collapse
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...
Stansberry Research | Sponsored
Trump announcement boosts “next Bitcoin”
President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...
Weiss Ratings | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored